TXMD logo

THERAPEUTICSMD INC

TXMDNASDAQ
πŸ† #4010 by market capUS Equity
$2.10β–² $0.03 (+1.45%)
Live
1hβ€”
24hβ–² 1.4%
7dβ–² 2.7%
14dβ–² 2.4%
30dβ–² 5.3%
1yβ–² 90.0%
🏦Market Cap
$24M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+71.6%
High Growth
πŸ“ŠGross Margin
86.5%
High
πŸ’΅FCF Margin
130.7%
Strong
βš–οΈP/S Ratio
10.0x
Elevated
Otter Score
53
Weak

Trading Snapshot

Day Range
$2.07 – $2.12
52-Week Range
$0.99 – $2.95
Volume
$2.33B
Avg Volume
$2.66B
Shares Outstanding
11.6M
Next Earnings
Oct 28, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$759,693
P/E Ratio
-93.2
P/S Ratio
10.0x
EPS (TTM)
$-0.02
Dividend Yield
0.00%

Why Investors Own TXMD

  • βœ“High-growth profile β€” revenue up +2.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 36% gross margin and 28% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$3Mβ–² +1.6% YoY
Gross Margin (TTM)
36.1%β–Ό βˆ’0.5% YoY
Operating Income (TTM)
$637,642β–² +1.6% YoY
Free Cash Flow (TTM)
$858,248β–² +1.6% YoY

About THERAPEUTICSMD INC

TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
53/100

Analyst Ratings

β“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Feb 2024

Latest News & Updates